Tempero Bio, Inc., a clinical-stage biopharmaceutical company developing transformative treatments for substance use disorders, today announced the closing of a $70 million Series B financing. The ...
An international research team has conceived a dual-component controller for three-phase inverters that can reportedly ...
Ulcerative colitis (UC) is one of the most severe chronic diseases, causing relentless gastrointestinal pain and ...
Peeples Cancer Institute at Hamilton Medical Center has expanded access to the latest in cancer research for patients in ...
The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...
"We are excited to initiate the Phase 3 study and we believe that Piclidenoson's oral dosage and excellent safety record, ...
A recent study found that toxicity is routinely minimized in phase 3 oncology trials, especially those that are not industry ...
Duke University blood cancer specialist Lindsay Rein, MD, has developed a rare expertise in myeloproliferative neoplasms ...
Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.
More than 100,000 nonhuman primates, including baboons, macaques, marmosets, and other monkeys, are held or used for research ...
NIH has launched a human trial for LASSARAB, a dual-purpose vaccine targeting Lassa fever and rabies. Early animal studies ...
Vietnam Investment Review on MSN9h
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 for Platinum resistant Ovarian CancerSAN FRANCISCO and SUZHOU, China, March 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback